BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease
Status:
RECRUITING
Trial end date:
2027-05-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of IPX203 (Crexont) - the newest extended-release levodopa formulation - on the duration and quality of good on time, using a wearable device to monitor symptoms. 'Good on time' refers to a period (minutes to hours) when a patient experiences optimal symptom control due to effective medication and has better overall functioning without troublesome dyskinesias. The change in the duration and quality of on-time will be measured by a wearable device placed on your wrist called KinesiaU.